RPG Life Sciences Limited
RPGLIFERPG Life Sciences Limited
RPGLIFE
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.23 | 10.98 | 0.64% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
RPG Life Sciences Limited is engaged in manufacturing and marketing of pharmaceutical products. The Company operates across segments, including Domestic Formulations, International Formulations, Active Pharmaceutical Ingredients (API) and Biotech.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 280.10 | 303.17 | 344.93 | 330.96 | 376.30 | 390.05 | 443.15 | 517.61 | 589.26 | 626.20 | ||||||||||
Raw Materials | 93.85 | 112.21 | 121.30 | 96.33 | 133.74 | 136.11 | 167.03 | 178.17 | 181.83 | 502.00 | ||||||||||
| Power & Fuel Cost | 11.23 | 9.10 | 10.44 | 10.38 | 11.54 | 11.27 | 12.69 | 13.65 | 14.36 | |||||||||||
| Employee Cost | 74.13 | 75.59 | 90.14 | 89.93 | 90.97 | 94.66 | 99.97 | 117.06 | 132.15 | |||||||||||
| Selling & Administrative Expenses | 38.80 | 55.41 | 63.13 | 59.43 | 56.84 | 58.40 | 67.07 | 73.63 | 80.47 | |||||||||||
| Operating & Other expenses | 37.83 | 12.45 | 20.50 | 39.66 | 27.64 | 17.77 | 6.15 | 26.77 | 44.10 | |||||||||||
EBITDA | 24.26 | 38.41 | 39.42 | 35.23 | 55.57 | 71.84 | 90.24 | 108.33 | 136.35 | 124.20 | ||||||||||
| Depreciation/Amortization | 10.15 | 11.31 | 14.34 | 15.32 | 16.36 | 16.47 | 15.66 | 15.50 | 17.07 | 19.23 | ||||||||||
| PBIT | 14.11 | 27.10 | 25.08 | 19.91 | 39.21 | 55.37 | 74.58 | 92.83 | 119.28 | 104.97 | ||||||||||
| Interest & Other Items | 2.49 | 3.64 | 4.72 | 4.86 | 2.76 | 1.79 | 1.41 | 1.15 | 1.44 | 0.60 | ||||||||||
| PBT | 11.62 | 23.46 | 20.36 | 15.05 | 36.45 | 53.58 | 73.17 | 91.68 | 117.84 | 104.37 | ||||||||||
| Taxes & Other Items | 0.00 | 2.45 | 6.91 | 4.24 | 7.44 | 13.58 | 21.69 | 24.04 | 30.18 | 33.71 | ||||||||||
| Net Income | 11.62 | 21.01 | 13.45 | 10.81 | 29.01 | 40.00 | 51.48 | 67.64 | 87.66 | 70.66 | ||||||||||
| EPS | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 42.72 | ||||||||||
| DPS | 1.60 | 2.80 | 2.40 | 2.40 | 4.00 | 7.20 | 9.60 | 12.00 | 16.00 | 16.00 | ||||||||||
| Payout ratio | 0.23 | 0.22 | 0.30 | 0.37 | 0.23 | 0.30 | 0.31 | 0.29 | 0.30 | 0.37 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| RPG Life Sciences Limited | 46.94 | 10.98 | 0.64% |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare RPGLIFE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.02%
Top 5 Mutual Funds holding RPG Life Sciences Limited
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Mirae Asset Multicap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.3899% | Percentage of the fund’s portfolio invested in the stock 1.77% | Change in the portfolio weight of the stock over the last 3 months 0.39% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/101 (+1) |
Quant Active Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9998% | Percentage of the fund’s portfolio invested in the stock 0.42% | Change in the portfolio weight of the stock over the last 3 months 0.42% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 58/66 (+7) |
Quant Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8681% | Percentage of the fund’s portfolio invested in the stock 8.78% | Change in the portfolio weight of the stock over the last 3 months 6.61% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 1/27 (+11) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Increasing Dividends
RPGLIFE has increased dividends consistently over the last 5 years
Dividend Yield
Current dividend yield is 0.64%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.43 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 28, 2024
Dividend/Share
₹16.00
Ex DateEx Date
Jun 28, 2024
Cash Dividend
Ex DateEx DateJul 21, 2023
Dividend/Share
₹12.00
Ex DateEx Date
Jul 21, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹9.60
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateAug 13, 2021
Dividend/Share
₹7.20
Ex DateEx Date
Aug 13, 2021
Cash Dividend
Ex DateEx DateMar 24, 2020
Dividend/Share
₹4.00
Ex DateEx Date
Mar 24, 2020
Net profit of RPG Life Sciences declined 83.76% to Rs 4.20 crore in the quarter ended September 2024 as against Rs 25.86 crore during the previous quarter ended September 2023. Sales rose 12.13% to Rs 172.21 crore in the quarter ended September 2024 as against Rs 153.58 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales172.21153.58 12 OPM %26.6724.28 - PBDT47.7039.02 22 PBT42.3934.79 22 NP4.2025.86 -84 Powered by Capital Market - Live
RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live
Harsh Goenka-backed RPG Life Sciences surges 15% on solid Q1FY25 results
RPG Life Sciences standalone net profit rises 21.09% in the June 2024 quarter
Q2 Review: RPG Life Sciences MD On Q2 Report Card & More | BQ Prime
RPG Life Sciences Shares Rise To Record High After Q2 Profit Surge
RPG Life Sciences hits 52-week high as Q1 profit surges 22%
We expect profitability to continue: Yugal Sikri, RPG Life Sciences
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.23%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.15% to 0.16%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 51.98%, vs industry avg of 15.28%